1 / 13

PREVENTION OF RHEUMATIC FEVER

PREVENTION OF RHEUMATIC FEVER. Dr. Animesh Mishra, DM (Delhi University) Associate Professor Department of Cardiology NEIGRIHMS Shillong-12. What is Acute Rheumatic fever ?. Infectious Immunological Genetic Collagen Vascular Disease Or an unidentified factor. ?.

constance-kim
Télécharger la présentation

PREVENTION OF RHEUMATIC FEVER

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. PREVENTION OF RHEUMATIC FEVER Dr. Animesh Mishra, DM (Delhi University) Associate Professor Department of Cardiology NEIGRIHMS Shillong-12

  2. What is Acute Rheumatic fever ? • Infectious • Immunological • Genetic • Collagen Vascular Disease • Or an unidentified factor. ?

  3. Is It Possible to Prevent Rheumatic Fever ? • Primordial Prevention • Primary Prevention • Secondary Prevention

  4. Primordial prevention Preventing the development of ‘risk factors’ Measures for Primordial Prevention 1- Improvement in Socio-Economic Status 2- Prevention of overcrowding 3- Availability of Prompt Medical care 4- Public Education

  5. Primary Prevention Measures for Primary Prevention Identification (GAS) Eradication (Penicillin) Susceptible individuals ? Anti Streptococcal Vaccine • Theoretical possibility at the community but Possible at individual level

  6. Community level prevention ‘Sledge Hammer Approach’ 3%-20% of sore throat are GAS .3% of GAS sore throat result in RF 90% of Patients of RF develops RHD 10000 Sore throats 10000 3%-20% GAS 2000 300 1 .3% RF 6 . 90%RHD 5 1

  7. Identification and Eradication of GAS -Not Feasible at community level 1- Asymptomatic sore throat 2- Diagnosis at mass level 3- Identification Methods not 100%senstive and specific 4- Route of infection 5- Non compliance with the oral Treatment 6- Treatment failure (Penicillin failure)

  8. Susceptible individuals • HLA-D 1,2,3,4 • HLA –D 8/17 Indian population • B cell alloantigen Results can not be utilized at community level

  9. Rheumatic Vaccine Strain specific M-Protein Caveats 1-Hundreds of Strains 2- Fast mutation rate 3- Virulent GAS may not produce M-Protein Polyvalent vaccines- Tried, but not successful

  10. Conserved C-Terminus of M-protein C-5a Peptidase Fibro nectin surface binding Protein (sfb-1) Chemaric peptide J8 Polysaccharide conjugated with protein

  11. Health Education (5-16 years) Education by Parents Teachers All India Radio Doordarshan NICs, CICs

  12. Health Education (5-16 years) Education by Parents Teachers All India Radio Doordarshan NICs, CICs

  13. Secondary PreventionSecondary Attack Rate -50% • Penicillin Prophylaxis – Every 2-3 weeks (Depending upon the Age, Wt, Muscle mass ) Duration of prophylaxis – LIFE LONG 10Yrs/ Adulthood 5Yrs/ 18Yrs. 1Yrs Anaphylactic Shock: 1: 1000000= 105 Secondary Prevention cannot reduce the burden of RHD SS

More Related